Earth

ΑD

CLINICAL TRIALS

Spirometer-Oximeter Manufacturer Pharma-clinical trials expertise

Health

Health

Northwick Park drug trial disaster - could it happen again?

By Philippa Roxby Health reporter, BBC News

24 May 2013 | Health



Before any new medicine can be given to patients, detailed information about how it works and how safe it is must be collected.

Clinical trials are the key to getting that data - and without volunteers to take part in the trials, there would be no new treatments for serious diseases such as cancer, multiple sclerosis and arthritis.

But one disastrous drug trial at a London hospital in 2006 threatened to derail that system.

In what became known as the Elephant Man trial, <u>six healthy young men were treated for organ failure</u> after experiencing a serious reaction within hours of taking the drug TGN1412 in a clinical trial.

After they were all admitted to intensive care, two became critically ill, the worst affected lost his fingers and toes, and all the men were subsequently told they would be likely to develop cancers or auto-immune diseases as a result of their exposure to the drug.

In follow-up interviews, the men described feeling like their brains were "on fire" and their "eyeballs were going to pop out".

Experts queued up to say the outcome of the trial had been unprecedented and exceptional, but could it happen again?

Prof David Webb, professor of therapeutics and clinical pharmacology at the University of Edinburgh and vice president of the British Pharmacological Society, says it is "much less likely to happen again".

He says things have changed for the better since 2006, following a number of recommendations made in the Duff Report, written in response to the trial.

"The MHRA [Medicines and Health products Regulatory Agency] now ensures committees look at pre-clinical data, to decide whether the first dose given to humans is the right dose and has rules for stopping if things don't go as expected."

This is particularly important when trials involve drugs that affect the immune system, he says.

But is it possible to eliminate the risks entirely?

"You can mitigate against the risks, but nothing is 100% certain. We can never be sure," Prof Webb says.

The trial, which was privately run at a research facility at Northwick Park Hospital in north London, involved the first testing of a new drug on humans. This is the initial phase in assessing the safety of a drug before moving onto larger-scales studies in patients themselves.

The report said **Parexel**, the company managing the trial, had been unclear about a safe dose to start testing on humans and it should have tested the drug on one person at a time.

The MHRA, which regulates clinical trials and medicines in the UK, and which was criticised at the time for giving the green light to the TGN1412 trial, says the conduct on these phase-one trials "has moved on significantly".

"Additional provisions and guidance has been put in place for certain novel products to provide as much assurance on safety as possible," the agency says.

It adds that it has simplified and streamlined the regulation of clinical trials and collaborated with other bodies and experts to collect as much information as possible on risk factors before a trial is authorised.

Phase-one trials, when drugs are tested on humans for the first time, only happen after extensive testing on tissue samples and animals in the lab.

Getting this stage right before moving onto research in humans is crucial.

Dr Catherine Elliott, director of clinical research interests at the Medical Research Council, which funds clinical trials in the UK and globally, says there is a move to refine the models used at the pre-clinical stage.



"Animal models are the mainstay, but we are trying to develop other models too to have more tailored disease models."

She says researchers are making use of brain imaging to understand the mechanisms of illness in humans and using IT to predict the effects of new drugs.

Testing on animals, which has its own controversies, can get scientists so far - but someone always has to be the first person to test a new medicine.

The volunteers for phase-one clinical tests always have to be healthy young men because of the risk to a woman's eggs or foetus.

Prof Webb says we are indebted to the 50 to 100 people in the UK each year who step forward to begin the testing of every new drug.

"There are so many effective medicines for cancer, heart disease et cetera - and they all come from volunteers who have taken part in small, early studies."

He believes that everyone who wants to should be able to register themselves available for clinical research through their GP.

"I would argue that everyone should be a volunteer. We'd get the payback eventually because by the time we're in our 60s and 70s most of us will end up on medicines."

Although volunteers are compensated for their time and inconvenience during the trial, they are not paid for taking part - and Dr Elliott says this is the correct approach.

"There shouldn't be an incentive to do something they wouldn't otherwise do. It shouldn't be related to risk. People have to be able to give free consent."

Despite all this, there appears to have been no reduction in interest in participating in early-stage trials since Northwick Park.

The MHRA says the number of UK clinical trial authorisation applications has been fairly stable at 900-1,000 per year since May 2004.

Prof Webb says he has always found it relatively easy to find volunteers for the "first in man" trials he oversees at his approved research centre in Edinburgh.

The MHRA is in no doubt about the safety of drug trials, seven years on from Northwick Park.

A representative said: "Clinical trials in the UK have an excellent safety record and they play a vital role in the development of new medicines, providing evidence so that clinicians can make informed prescribing decisions.

"Safety problems associated with clinical trials are rare and the risk of a repeat of the incident in 2006 concerning the TGN1412 drug is extremely low."

Share this story About sharing

More on this story

Big rise in volunteers for medical trials

24 May 2013

Moving on from drug trial horror

13 March 2007

Expert drug trial safety advice

7 December 2006

'Facing up to my uncertain future'

7 December 2006

Drug trials tragedy - who is liable?

21 March 2006

Related Internet links

Department of Health

Parexel

British Pharmacological Society

Medical Research Council

Medicines and Healthcare products Regulatory Agency (MHRA)

The BBC is not responsible for the content of external Internet sites

More Health stories




Child mental health 'faces overhaul'

32 minutes ago



'Army of pharmacists' to help GPs

13 minutes ago



Ebola: Seventh Brit sent home 16 March 2015

More Videos from the BBC



Woman 'lost job chance' over hair



Saudi's Secret Uprising



Michelle Obama shows off her moves



Lawyer: 'Durst didn't kill Susan Berman'



Music videos without the, um, music



Prince Harry set to leave Army

Recommended by Outbrain

Elsewhere on BBC

Clarkson to 'move on?' - front pages BBC News

Top 10 cars at the 2015 Geneva motor show

Woman killed by whale off Mexico BBC News

400-year-old boarding school shuts BBC News

Recommended by Outbrain

Netanyahu and a centre-left alliance.

1 hour ago

Pakistan carries out mass hangings

2 hours ago

Spain finds tomb of writer Cervantes

14 minutes ago

BBC Autos

Top Stories

Netanyahu battles for fourth term

Polls open in Israel in what is expected to be a close fight between Prime Minister Benjamin





Pay as ewe like

The country where you can pick a tax rate - and even pay in rams



A Yemen journey
Travelling through a country on the brink of falling apart



Rural reach
Bringing cataract ops to remote regions



Chill outWhy egg-freezing parties are on the rise



Brothers accusedFamily fights to clear names of Nemtsov murder suspects



Videos minus the music
What do pop videos 'sound' like without the tunes?



Handle with care Who will look after Japan's elderly?



Sit on it

The Detroit bus that double as public libraries

Most Popular

Read

Watched

- 1 Pakistan carries out mass hangings
- 2 Spain finds tomb of writer Cervantes
- 3 The country where you can choose your tax rate
- 4 Netanyahu battles for fourth term
- 5 'Kidnapped' Dutch kids brought to IS
- 6 Rosetta comet wind mystery 'solved'
- 7 Gold ingot seized in Argentina
- 8 Damage 'worse' on Vanuatu islands
- 9 McDonald's burns prompt US inquiry
- 1 Michelle Obama shows off her moves
- 2 Woman 'lost job chance' over hair
- 3 Music videos without the, um, music
- 4 Blackwood 'disappointed' in verdict
- 5 Skydiving 100-year-old now shark diving
- 6 One-minute World News
- 7 'My sons did not kill Boris Nemtsov'
- 8 Boko Haram escapees in the US
- 9 Inside the FBI's massive gun vault
- 10 'Jihadi bride' denies recruiting girls

From Around the Web

Nigeria's Fast Growing Manufacturing Sector Nigeria Next

Here's What Will Send Oil Prices Back Up Again TalkMarkets

5 Metrics Every Presenter Should Know

Prezi

5 Great Buys

TalkMarkets

Nigeria's Rapidly Growing Car Market

Nigeria Next

Chinese gold mystery- Where are all those imports from Switzerland going?

Nikkei Asian Review

Promoted content by Outbrain

Ads by Google

READY for Article 57

XEVMPD and ISO IDMP, Fast implementation and Validation www.nanokinetik.com

Human Abuse Liability

Industry leader in a diverse range of Human Abuse Liability studies www.vinceandassociates.com/HAL

Beauty Samples - Free

Try Top of the Line Skin Products. Apply Now for Free Samples. lifestylebeautytipz.com/ukskin

BBC News Services

On your mobile

On your connected TV

Get news alerts

Contact BBC News

Explore the BBC

News Weather Earth Capital Autos Sport Shop Travel Culture Future Radio CBBC
WW1
Food
History
Learning
Music
Nature
Full A-Z

CBeebies
Food
Learning
Learning
Science
Local

Desktop Site Terms of Use

About the BBC Privacy Policy

Cookies Accessibility Help

Parental Guidance Contact the BBC

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.